1. NBS superfood: a promising adjunctive therapy in critically ill ICU patients with omicron variant of COVID-19
- Author
-
Mehrdad Mosadegh, Aref Khalkhali, Yousef Erfani, Manije Nezamdoost, Seyyed Hamid Hashemi, Farid Azizi Jalilian, Nastaran Ansari, Shahab Mahmoudvand, Mojgan Mamani, Elham Abdoli, Razieh Amini, and Gholamreza Kalvandi
- Subjects
Nutrition bio-shield ,SARS-CoV-2 Omicron variant ,COVID-19 ,Complementary therapies ,Respiratory distress syndrome ,Biotechnology ,TP248.13-248.65 ,Microbiology ,QR1-502 - Abstract
Abstract This clinical trial aimed to assess the impact of Nutrition Bio-shield superfood (NBS) on clinical status among critically ill ICU patients suffering from acute respiratory distress syndrome (ARDS) due to the Omicron variant of COVID-19. A total of 400 patients with confirmed Omicron-related ARDS were randomly assigned to either the intervention group (n = 200) or the control group (n = 200). Patients in the intervention group received 1.5 g of NBS powder daily for 2 weeks in addition to standard antiviral treatment, while the control group received a placebo alongside standard antiviral therapy. Serum samples were collected from all patients in both groups, and various clinical and laboratory parameters, including ESR, CRP, D-Dimer, CPK, WBC count, lymphocyte count, and lymphocyte percentage, were measured using established methodologies. Following a 14-day intervention period, the intervention group exhibited a significant reduction in mean serum levels of CRP (15.39 vs. 48.49; P
- Published
- 2024
- Full Text
- View/download PDF